Inhibikase Therapeutics Develops New Molecular Entity for Fatal Disease Revolutionizing Treatment for Fatal Disease In a groundbreaking development, Inhibikase Therapeutics, Inc. has initiated the development of IkT-001Pro as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60. This innovative approach marks a significant…

Quad/Graphics Completes Ninth Amendment to Bank Debt Agreement SUSSEX, Wis., Oct. 21, 2024 /PRNewswire/ — Quad/Graphics, Inc. (NYSE: QUAD), a global marketing experience company, announced today that it has completed the ninth amendment to the company’s bank debt agreement. This amendment includes various changes to the existing revolving credit facility and term loan facility, as…

Latin Metals Receives Key Permit for Esperanza Project Exploration VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) — Latin Metals Inc. (“Latin Metals” or the “Company”) – (TSXV: LMS) (OTCQB: LMSQF) Latin Metals Inc. is pleased to announce that it has received a key permit to begin exploration activities at the Esperanza project. This is…

Get Ready to Laugh: Southern States Bancshares Inc. Shares Hilarious Third Quarter 2024 Financial Results! Description: Third Quarter 2024 Performance and Operational Highlights: Net income of $7.4 million, or $0.76 per diluted share Core net income of $8.7 million, or $0.89 per diluted share Core pretax pre-provision net income of $13.8 million Net interest income…

Welcome to the Novo Nordisk Cardiovascular Outcomes Trial Bagsværd, Denmark, 21 October 2024 Exciting News from Novo Nordisk! Today, Novo Nordisk announced the headline results from the SOUL cardiovascular outcomes trial, and it’s big news! The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of…

Introducing IBM’s Granite 3.0: The Ultimate AI Models for Business Success! Description: New Granite 3.0 8B & 2B models, released under the permissive Apache 2.0 license, show strong performance across many academic and enterprise benchmarks, able to outperform or match similar-sized models. The new Granite Guardian 3.0 models deliver IBM’s most comprehensive guardrail capabilities to…